Clinical Progress and Preclinical Insights Into Umbilical Cord Blood Transplantation Improvement

The application of umbilical cord blood (UCB) as an important source of hematopoietic stem and progenitor cells (HSPCs) for hematopoietic reconstitution in the clinical context has steadily grown worldwide in the past 30 years. UCB has advantages that include rapid availability of donors, less strict HLA-matching demands, and low rates of graft-versus-host disease (GVHD) versus bone marrow (BM) and mobilized peripheral blood (PB). However, the limited number of HSPCs within a single UCB unit often leads to delayed hematopoietic engraftment, increased risk of transplant-related infection and mortality, and proneness to graft failure, thus hindering wide clinical application. Many strategies have been developed to improve UCB engraftment, most of which are based on 2 approaches: increasing the HSPC number ex vivo before transplantation and enhancing HSPC homing to the recipient BM niche after transplantation. Recently, several methods have shown promising progress in UCB engraftment improvement. Here, we review the current situations of UCB manipulation in preclinical and clinical settings and discuss challenges and future directions.

Automated summary

The application of umbilical cord blood (UCB) as a source of hematopoietic stem and progenitor cells (HSPCs) has grown worldwide in the past 30 years. UCB has advantages of rapid donor availability, less strict HLA-matching demands, and low rates of graft-versus-host disease (GVHD). However, the limited number of HSPCs within a single UCB unit poses challenges for wide clinical application. Strategies to improve UCB engraftment have been developed, focusing on increasing HSPC numbers and enhancing HSPC homing to the recipient BM niche.